Investor Presentaiton

9M FY22 Geographical Performance ROW 4.3% Australia 10.1% Europe, UK 42.3% ◉ Commentary on Geographical Performance US, North America was the highest contributor at #463.5 cr. and witnessed 2.9% growth in 9MFY22 ■ EU, UK formulations market recorded 2.6% growth at 454.1 cr. in 9MFY22 ■ Australia, NZ formulation markets recorded 4.3% growth at 108.7 cr. in 9MFY22 ■ Rest of World recorded 5.0% decrease with sales of 46.5 cr, in 9MFY22 due to logistics issues US & North America 43.2% ©2021 - Marksans Pharma Limited, All Rights Reserved. 8

View entire presentation